GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reneo Pharmaceuticals Inc (NAS:RPHM) » Definitions » EPS (Diluted)

Reneo Pharmaceuticals (Reneo Pharmaceuticals) EPS (Diluted) : $-2.18 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reneo Pharmaceuticals EPS (Diluted)?

Reneo Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.25. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.18.

Reneo Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-0.25. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.18.

Reneo Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was $-0.25. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.18.

During the past 3 years, the average EPS without NRIGrowth Rate was -46.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Reneo Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was -9.90% per year. The lowest was -46.30% per year. And the median was -28.10% per year.


Reneo Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Reneo Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reneo Pharmaceuticals EPS (Diluted) Chart

Reneo Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-1.60 -0.80 -2.19 -2.12 -2.52

Reneo Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.60 -0.65 -0.57 -0.71 -0.25

Competitive Comparison of Reneo Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Reneo Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reneo Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reneo Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Reneo Pharmaceuticals's PE Ratio falls into.



Reneo Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Reneo Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-77.388-0)/30.676
=-2.52

Reneo Pharmaceuticals's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-8.426-0)/33.421
=-0.25

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reneo Pharmaceuticals  (NAS:RPHM) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Reneo Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Reneo Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Reneo Pharmaceuticals (Reneo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
18575 Jamboree Road, Suite 275-S, Irvine, CA, USA, 92612
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
Executives
Ashley Hall officer: Chief Development Officer C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Michael Cruse officer: Senior VP, Corporate Operation C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jennifer Lam officer: VP of Finance & Administration C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S, IRVINE CA 92612
Paul W. Hoelscher director 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Vineet R. Jindal officer: Chief Financial Officer C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Gregory J. Flesher director, officer: President and CEO 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Wendy S. Johnson officer: Chief Development Officer 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Rivervest Venture Fund Iii (ohio), L.p. 10 percent owner 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Rivervest Venture Fund Iii, L.p. 10 percent owner 7733 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Stacey Denenberg Seltzer director C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106